Anthea Wirges is addressing the limitations of durable Chimeric Antigen Receptor (CAR) T cell therapies in hematological malignancies, which suffer from relapses and resistances despite impressive initial response rates. Her solution involves the creation of novel CAR T cells targeting a unique antigen and employing a distinct mode of action to address both the tumor and its supporting microenvironment, aiming to prevent the risk of tumor relapse.

Further Activities to have a look at